• Alias: T-VEC; GM-CSF encoding oncolytic HSV
    • A genetically modified attenuated HSV oncolytic virus that selectively replicates in and lyses tumor cells. It is modified through the deletion of two viral genes, ICP24.5 and ICP47. Virally derived GM-CSF recruits and activates antigen-presenting cells, leading to antitumor immune response.
    • FDA approved for unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery
    • Recommended dose: Intralesional injection into cutaneous, subcutaneously, and/or nodal lesions that are visible, palpable, or detectable. Inject up to 4 mL at a concentration of 1 million   til maximum injectable volume is reached. May give second injection 3 weeks after initial treatment at 4 mL at a concentration of 100 million PFU/mL. May give subsequent injections 2 weeks after previous treatment.
    Other topics in Targeted and Immunotherapy Agents